In order to address whether Fn can also target immature, stem-like CRC cells, we took advantage of a patient-derived CSC line (CSC-P) cultivated in defined serum-free medium and previously characterized for its tumorigenicity in vivo [19]. This evidence concerns the gene FN1 and colorectal carcinoma.